95 related articles for article (PubMed ID: 22103058)
1. Immediate post-operative hypersensitivity reaction to Cetuximab in patients preoperatively treated by the monoclonal antibody: what's wrong?
Delaunoit T
Acta Gastroenterol Belg; 2011 Sep; 74(3):475-6. PubMed ID: 22103058
[No Abstract] [Full Text] [Related]
2. Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab.
Nielsen DL; Pfeiffer P; Jensen BV
Ann Oncol; 2009 Apr; 20(4):798. PubMed ID: 19254943
[No Abstract] [Full Text] [Related]
3. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
4. A patient on targeted therapy: cetuximab.
Vogel WH
Oncology (Williston Park); 2006 Sep; 20(10 Suppl Nurse Ed):25-7. PubMed ID: 18153976
[No Abstract] [Full Text] [Related]
5. Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports.
Nielsen DL; Pfeiffer P; Jensen BV
Acta Oncol; 2006; 45(8):1137-8. PubMed ID: 17118853
[No Abstract] [Full Text] [Related]
6. Cetuximab-associated infusion reactions: pathology and management.
Patel DD; Goldberg RM
Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases.
Petrelli NJ
J Clin Oncol; 2009 Apr; 27(11):1917; author reply 1918. PubMed ID: 19255304
[No Abstract] [Full Text] [Related]
8. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management.
Kang SP; Saif MW
J Support Oncol; 2007 Oct; 5(9):451-7. PubMed ID: 18019853
[No Abstract] [Full Text] [Related]
9. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
10. How many patients and how many complications does it take to decide if a drug is safe to use before surgery?
Kemeny MM
J Clin Oncol; 2009 Apr; 27(11):1917-8; author reply 1918. PubMed ID: 19255303
[No Abstract] [Full Text] [Related]
11. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
Rodriguez NA; Ascaso FJ
J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
[No Abstract] [Full Text] [Related]
12. [Blepharitis related to Cetuximab treatment in an advanced colorectal cancer patient].
Ramírez-Soria MP; España-Gregori E; Aviñó-Martínez J; Pastor-Pascual F
Arch Soc Esp Oftalmol; 2008 Nov; 83(11):665-8. PubMed ID: 19006019
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
14. [Incidence of infusion reactions induced by cetuximab chemotherapy].
Maeda T; Tatematsu M; Muro K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
[TBL] [Abstract][Full Text] [Related]
15. Managing drug infusion reactions: focus on cetuximab monoclonal antibody therapy.
Wilkes G
Clin J Oncol Nurs; 2008 Jun; 12(3):530-2. PubMed ID: 18515254
[No Abstract] [Full Text] [Related]
16. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
[TBL] [Abstract][Full Text] [Related]
17. Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.
Dranko S; Kinney C; Ramanathan RK
Clin Colorectal Cancer; 2006 Sep; 6(3):224-5. PubMed ID: 17026793
[TBL] [Abstract][Full Text] [Related]
18. Successful management of infusion reaction accompanying the start of cetuximab therapy.
Melichar B; Cerman J; Malírová E
Support Care Cancer; 2007 Apr; 15(4):445-9. PubMed ID: 17103198
[TBL] [Abstract][Full Text] [Related]
19. Blepharitis and trichomegaly induced by cetuximab.
Criado PR; Lima AA
An Bras Dermatol; 2010; 85(6):919-20. PubMed ID: 21308323
[TBL] [Abstract][Full Text] [Related]
20. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
Hollywood E
Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
